ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

ClinicalTrials.gov ID: NCT06568237

Public ClinicalTrials.gov record NCT06568237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Study identification

NCT ID
NCT06568237
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • TEV-56286 Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2024
Primary completion
Sep 14, 2027
Completion
Sep 14, 2027
Last update posted
May 3, 2026

2024 – 2027

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
Teva Investigational Site 15554 La Jolla California 92037 Active, not recruiting
Teva Investigational Site 15545 Los Angeles California 90095 Not yet recruiting
Teva Investigational Site 15547 Washington D.C. District of Columbia 20007 Active, not recruiting
Teva Investigational Site 15544 Boca Raton Florida 33486 Active, not recruiting
Teva Investigational Site 15555 Tampa Florida 33613 Active, not recruiting
Teva Investigational Site 15550 Chicago Illinois 60612-3852 Active, not recruiting
Teva Investigational Site 15546 Kansas City Kansas 66160 Recruiting
Teva Investigational Site 15736 Boston Massachusetts 02115 Recruiting
Teva Investigational Site 15870 Farmington Hills Michigan 48334 Not yet recruiting
Teva Investigational Site 15552 Rochester Minnesota 55905 Recruiting
Teva Investigational Site 15549 New York New York 10016 Recruiting
Teva Investigational Site 15551 New York New York 10032-3726 Recruiting
Teva Investigational Site 15553 Durham North Carolina 27705-4410 Recruiting
Teva Investigational Site 15735 Hershey Pennsylvania 17033 Not yet recruiting
Teva Investigational Site 15548 Pittsburgh Pennsylvania 15213 Recruiting
Teva Investigational Site 15869 Georgetown Texas 78628 Not yet recruiting
Teva Investigational Site 15873 Alexandria Virginia 22310 Active, not recruiting
Teva Investigational Site 15543 Spokane Washington 99202 Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06568237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06568237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →